Hepatitis C Virus (HCV) by Molecular Method, Qualitative or Quantitative
The hepatitis C virus (HCV) is the most common cause of non-A and non-B hepatitis and accounts for >60% of all chronic cases of hepatitis. The Centers for Disease Control and Prevention (CDC) estimates there are approximately 17,000 new infections each year in the US and a total of 3.2 million chronic carriers. Of the newly infected, less than 25% will spontaneously eliminate the virus, with the remaining 75 - 85% becoming chronically infected. Patients that are chronically infected with HCV are at greater risk for developing chronic liver disease, cirrhosis, and hepatocellular carcinoma. Each year in the US 8,000 - 10,000 people die from HCV-related complications. Treatment exists for HCV and is often effective in totally eliminating the virus from the patient.
Infection is typically through contact with infected blood (i.e., IV drug abuse, needle sticks), blood products (prior to 1992), from mother to child, or contact with positive secretions. However, it has been shown that it is not easily spread via sexual contact. Other modes of HCV infection include dialysis, tattoos, and recipients of blood or organs from an HCV donor; however, these are fairly rare.
The HCV viral load assay detects HCV RNA in plasma or serum by reverse transcriptase PCR (RT-PCR) or branched DNA (bDNA) technology. It is approved for patients previously diagnosed with HCV using another method (it is not approved as a diagnostic assay). It is used for assessing the baseline viral load in HCV positive patients prior to the initiation of anti-HCV therapy, and for monitoring HCV viral RNA levels throughout the course of infection and in response to anti-viral therapy. Changes in the levels of HCV viral RNA during treatment may be helpful in early detection of potential therapeutic failure due to the emergence of a resistant virus and/or disease progression. Changes in viral load levels of at least 2 logs typically indicate the treatment is working, while changes in viral load levels less than 2 logs may indicate treatment failure. The HCV viral load level, however, is not a sole indicator of disease progression or severity. It should be used in conjunction with other clinical markers and laboratory tests.
- To establish a baseline prior to initiation of anti-HCV therapy
- Monitoring of patients with confirmed HCV infection
- Monitoring of patients undergoing anti-HCV therapy
Increased in:
- In infection with hepatitis C virus
- In patients with relapse or re-infection
Not detected (Negative)
Real-Time Reverse Transcriptase Polymerase Chain Reaction (RT-PCR), transcription mediated amplification (TMA).
Serum (SST), Plasma ACD (Yellow), PPT (White).
Stability
- Ambient: 1-3 days
- Refrigerated: 5-7 days
- Frozen: 30 days
- Scand J Infect Dis. 2011 Nov 8. PMID: 22066851]
- Hepatology. 1997 Sep;26(3 Suppl 1):43S-47S. [PMID: 9305663]
- J Clin Microbiol. 2008 Dec;46(12):3919-23. [PMID: 18945839]
- Clin Liver Dis. 1997 Nov;1(3):543-57, vi. [PMID: 15560057]
- Clin Chem. 2003;49:479. [PMID: 12600961]
- Clin Chem. 2003;49:940. [PMID: 12765991]